

Fiona J Thomson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6696226/publications.pdf>

Version: 2024-02-01

45
papers

1,166
citations

516561

16
h-index

377752

34
g-index

48
all docs

48
docs citations

48
times ranked

1516
citing authors

#	ARTICLE	IF	CITATIONS
1	Allosteric Modulation of the Cannabinoid CB1 Receptor. <i>Molecular Pharmacology</i> , 2005, 68, 1484-1495.	1.0	409
2	Innovative Approaches for the Treatment of Depression: Targeting the HPA Axis. <i>Neurochemical Research</i> , 2008, 33, 691-707.	1.6	128
3	Modulation of Hippocampal Synaptic Transmission by the Kynurenine Pathway Member Xanthurenic Acid and Other VGLUT Inhibitors. <i>Neuropsychopharmacology</i> , 2013, 38, 1060-1067.	2.8	47
4	Effect of the Glucocorticoid Receptor Antagonist Org 34850 on Basal and Stress-Induced Corticosterone Secretion. <i>Journal of Neuroendocrinology</i> , 2007, 19, 891-900.	1.2	44
5	Phosphatidylinositol 3-kinase, But Not p70 Ribosomal S6 Kinase, Is Involved in Membrane Protein Recycling: Wortmannin Inhibits Glucose Transport and Downregulates Cell-Surface Transferrin Receptor Numbers Independently of Any Effect on Fluid-phase Endocytosis in Fibroblasts. <i>Cellular Signalling</i> , 1996, 8, 297-304.	1.7	41
6	Blockade of the V1b receptor reduces ACTH, but not corticosterone secretion induced by stress without affecting basal hypothalamic-pituitary-adrenal axis activity. <i>Journal of Endocrinology</i> , 2009, 200, 273-283.	1.2	35
7	The priming effect of luteinizing hormone-releasing hormone (LHRH) but not LHRH-induced gonadotropin release, can be prevented by certain protein kinase C inhibitors. <i>Molecular and Cellular Endocrinology</i> , 1992, 85, 183-193.	1.6	34
8	Discovery of [¹¹ C]MK-6884: A Positron Emission Tomography (PET) Imaging Agent for the Study of M4 Muscarinic Receptor Positive Allosteric Modulators (PAMs) in Neurodegenerative Diseases. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 2411-2425.	2.9	30
9	Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study. <i>BMJ Open</i> , 2016, 6, e013324.	0.8	29
10	The relationship between glycine transporter 1 occupancy and the effects of the glycine transporter 1 inhibitor RG1678 or ORG25935 on object retrieval performance in scopolamine impaired rhesus monkey. <i>Psychopharmacology</i> , 2014, 231, 511-519.	1.5	27
11	The differential effects of protein kinase C activators and inhibitors on rat anterior pituitary hormone release. <i>Molecular and Cellular Endocrinology</i> , 1993, 94, 223-234.	1.6	26
12	Effect of vasopressin 1b receptor blockade on the hypothalamic-pituitary-adrenal response of chronically stressed rats to a heterotypic stressor. <i>Journal of Endocrinology</i> , 2009, 200, 285-291.	1.2	26
13	Characterization of a novel and selective V1B receptor antagonist. <i>Progress in Brain Research</i> , 2008, 170, 527-535.	0.9	22
14	Oestradiol-17 β modulates the actions of pharmacologically distinct forms of protein kinase C in rat anterior pituitary cells. <i>Journal of Endocrinology</i> , 1993, 136, 105-117.	1.2	21
15	Activation of serum response element-regulated genes by lysophosphatidic acid. <i>Nucleic Acids Research</i> , 1994, 22, 450-452.	6.5	17
16	Lysophosphatidic acid stimulates glucose transport in <i>Xenopus</i> oocytes via a phosphatidylinositol 3-kinase with distinct properties. <i>Biochemical Journal</i> , 1996, 316, 161-166.	1.7	17
17	Differential effect of glucocorticoid receptor antagonists on glucocorticoid receptor nuclear translocation and DNA binding. <i>Journal of Psychopharmacology</i> , 2011, 25, 211-221.	2.0	17
18	Iterative Focused Screening with Biological Fingerprints Identifies Selective Asc-1 Inhibitors Distinct from Traditional High Throughput Screening. <i>ACS Chemical Biology</i> , 2017, 12, 519-527.	1.6	16

#	ARTICLE	IF	CITATIONS
19	Developing a Low-Cost, Simple-to-Use Electrochemical Sensor for the Detection of Circulating Tumour DNA in Human Fluids. <i>Biosensors</i> , 2020, 10, 156.	2.3	13
20	The involvement of dihydropyridine-sensitive calcium channels in phorbol ester-induced luteinizing hormone and growth hormone release. <i>Molecular and Cellular Endocrinology</i> , 1993, 95, 31-41.	1.6	12
21	The discovery and SAR of indoline-3-carboxamides: A new series of 5-HT ₆ antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 3713-3716.	1.0	12
22	Characterization of the intracellular signalling pathways that underlie growth-factor-stimulated glucose transport in <i>Xenopus</i> oocytes: evidence for ras- and rho-dependent pathways of phosphatidylinositol 3-kinase activation. <i>Biochemical Journal</i> , 1997, 325, 637-643.	1.7	11
23	Effect of the glucocorticoid receptor antagonist Org 34850 on fast and delayed feedback of corticosterone release. <i>Journal of Endocrinology</i> , 2008, 196, 323-330.	1.2	11
24	Optimisation of an Electrochemical DNA Sensor for Measuring KRAS G12D and G13D Point Mutations in Different Tumour Types. <i>Biosensors</i> , 2021, 11, 42.	2.3	11
25	Serum Proteomics and Plasma Fibulin-3 in Differentiation of Mesothelioma From Asbestos-Exposed Controls and Patients With Other Pleural Diseases. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1705-1717.	0.5	10
26	Evidence for a role of phospholipase A2 in the mechanism of LHRH priming in rat anterior pituitary tissue. <i>Journal of Endocrinology</i> , 1994, 141, 15-31.	1.2	9
27	Pharmacological Characterization of the Novel and Selective $\alpha 7$ Nicotinic Acetylcholine Receptor-Positive Allosteric Modulator BNC375. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 373, 311-324.	1.3	9
28	Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT). <i>Radiation Oncology</i> , 2021, 16, 163.	1.2	9
29	Differential involvement of phospholipase A2 in phorbol ester-induced luteinizing hormone and growth hormone release from rat anterior pituitary tissue. <i>Molecular and Cellular Endocrinology</i> , 1993, 95, 75-83.	1.6	8
30	Discovery and optimisation of a selective non-steroidal glucocorticoid receptor antagonist. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 137-140.	1.0	8
31	Inhibition of depolarisation-induced calcium influx into GH3 cells by arachidonic acid: the involvement of protein kinase C. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1991, 1094, 346-354.	1.9	7
32	Properties and [32P] phosphorylation targets of a novel form of protein kinase C in pituitary. <i>Biochemical Society Transactions</i> , 1992, 20, 133S-133S.	1.6	7
33	Evidence that protein kinase C δ has reduced affinity towards 1,2-dioctanoyl-sn-glycerol: the effects of lipid activators on phorbol ester binding and kinase activity. <i>European Journal of Pharmacology</i> , 1993, 246, 9-18.	2.7	7
34	Identification and optimization of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V3 (V1b) receptor antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 5394-5397.	1.0	7
35	Synthesis and SAR studies of novel 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl)acetamide vasopressin V1b receptor antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 1871-1875.	1.0	7
36	V1A receptor antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 3163-3167.	1.0	7

#	ARTICLE	IF	CITATIONS
37	Differential activation of phospholipase A2 by protein kinase C in pituitary cells. Biochemical Society Transactions, 1991, 19, 117S-117S.	1.6	5
38	Does inositol hexakisphosphate induce Ca ²⁺ entry into GH3 cells?. Biochemical Society Transactions, 1991, 19, 116S-116S.	1.6	3
39	Hormonal regulation of the insulin-responsive glucose transporter, GLUT4: some recent advances. Proceedings of the Nutrition Society, 1996, 55, 179-190.	0.4	3
40	Evidence for <i>ras</i> - and <i>rho</i> -dependent pathways in the regulation of glucose transport by growth factors. Biochemical Society Transactions, 1997, 25, 472S-472S.	1.6	1
41	Protein kinase C-dependent and -independent actions of arachidonic acid in GH3 cells. Biochemical Society Transactions, 1991, 19, 115S-115S.	1.6	0
42	The calcium signalling M1 muscarinic receptor regulates gene expression under cAMP response element control. Biochemical Society Transactions, 1999, 27, A119-A119.	1.6	0
43	B17 IN VITRO AND IN VIVO CHARACTERIZATION OF THE VASOPRESSIN RECEPTOR ANTAGONIST SSR149415. Behavioural Pharmacology, 2005, 16, S71.	0.8	0
44	Identification and optimisation of novel sulfonamide, selective vasopressin V1B receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 3603-3607.	1.0	0
45	Electrochemical DNA Detection Methods to Measure Circulating Tumour DNA for Enhanced Diagnosis and Monitoring of Cancer. Proceedings (mdpi), 2020, 60, 15.	0.2	0